Pacific Biosciences of California Inc

PACB

1.820USD

+0.105+6.12%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Pacific Biosciences of California Inc's Score

Industry at a Glance

Industry Ranking

115 / 205

Overall Ranking

296 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Pacific Biosciences of California Inc Highlights

StrengthsRisks

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 20.04% year-on-year.

Overvalued

The company’s latest PE is -1.09, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 169.14M shares, decreasing 27.90% quarter-over-quarter.

Held by Murray Stahl

Star Investor Murray Stahl holds 11.52K shares of this stock.

Analyst Rating

Based on 9 analysts

Hold

Current Rating

2.214

Target Price

+13.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Pacific Biosciences of California Inc is 5.64, ranking 192 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 38.44M, representing a year-over-year decrease of 3.82%, while its net profit experienced a year-over-year decrease of 37.42%.

Score

Industry at a Glance

Previous score

5.64

Change

0



Financials

4.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.93

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

5.48

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.68

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Pacific Biosciences of California Inc is 7.84, ranking 55 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -1.09, which is -63.28% below the recent high of -0.40 and -842.26% above the recent low of -10.27.

Score

Industry at a Glance

Previous score

7.84

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 115/205

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Pacific Biosciences of California Inc is 6.89, ranking 155 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 2.50, with a high of 3.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

6.89

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Pacific Biosciences of California Inc is 5.77, ranking 170 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 2.47 and the support level at 1.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.62

Change

0.15

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Pacific Biosciences of California Inc is 5.00, ranking 113 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 56.02%, representing a quarter-over-quarter increase of 1.28%. The largest institutional shareholder is Catherine Wood, holding a total of 37.26M shares, representing 12.34% of shares outstanding, with 1.54% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

30.92M

-14.81%

SoftBank Group Corp

20.45M

--

BlackRock Institutional Trust Company, N.A.

19.86M

-0.52%

The Vanguard Group, Inc.

Star Investors

16.38M

+2.27%

Edmond de Rothschild Asset Management (France) S.A.

10.68M

-20.13%

Amova Asset Management Co., Ltd.

8.68M

-5.87%

Geode Capital Management, L.L.C.

6.91M

+2.79%

State Street Investment Management (US)

5.91M

+2.69%

Madrone Advisors, LLC

4.98M

-70.31%

Millennium Management LLC

4.92M

+466.29%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Pacific Biosciences of California Inc is 3.44, ranking 124 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 2.31. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Pacific Biosciences of California Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Pacific Biosciences of California Inc

PACB

5.96 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

LivaNova PLC

LIVN

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cencora Inc

COR

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Becton Dickinson and Co

BDX

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AxoGen Inc

AXGN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Align Technology Inc

ALGN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment